{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-021658","form_type":"8-K","ticker":"VNDA","cik":"0001347178","company_name":"Vanda Pharmaceuticals Inc.","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.037844+00:00","generated_at":"2026-06-02T09:06:05.631180+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Vanda Q1 revenue $47.5M, net loss $4.1M; Fanapt bipolar approval, PONVORY launch in Q3","bullets":["Net loss $4.1M (diluted EPS -$0.07) vs net income $3.3M ($0.06) in Q1 2023; revenue $47.5M, -24% YoY.","Cash increased $5.9M to $394.1M; Fanapt approved for acute bipolar I disorder, launch Q3 2024.","PONVORY commercial launch in multiple sclerosis expected Q3 2024; tradipitant NDA for gastroparesis under FDA review with PDUFA Sept 18, 2024.","Milsaperidone NDA for schizophrenia and bipolar expected early-2025; tradipitant motion sickness Phase III results Q2 2024.","No FY 2024 guidance given due to HETLIOZ generic competition and upcoming launches."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-021658","json":"https://secwatch.observer/filing/0001628280-24-021658.json","markdown":"https://secwatch.observer/filing/0001628280-24-021658.md","text":"https://secwatch.observer/filing/0001628280-24-021658.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1347178/000162828024021658/0001628280-24-021658-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1347178/000162828024021658/vnda-20240508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T09:06:05.631180+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bc5a0fbce2be2c2dbd70f10b1a7bba1f23a05d40","claim":"Vanda Pharmaceuticals Inc. reported first quarter ended March 31, 2024 results: revenue $47.5 million, net income $(4.1) million.","evidence_excerpt":"Financial Highlights • Total net product sales from Fanapt ® , HETLIOZ ® and PONVORY ® were $47.5 million in the first quarter of 2024, a 24% decrease compared to $62.5 million in the first quarter of 2023, and a 5% increase compared to $45.3 million in the fourth quarter of 2023. • Fanapt ® net product sales were $20.6 million in the first quarter of 2024, a 10% decrease compared to $22.9 million in the first quarter of 2023, and a 9% decrease compared to $22.6 million in the fourth quarter of 2023. • HETLIOZ ® net product sales were $20.1 million in the first quarter of 2024, a 49% decrease compared to $39.6 million in the first quarter of 2023, and a 5% decrease compared to $21.1 million in the fourth quarter of 2023. The decrease relative to the first quarter of 2023 was the result of continued generic competition in the U.S. • PONVORY ® net product sales were $6.8 million in the first quarter of 2024. The acquisition of PONVORY ® from Actelion Pharmaceuticals Ltd. (Janssen), a Joh","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1347178/000162828024021658/0001628280-24-021658-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$47.5 million"},{"label":"Net income","value":"$(4.1) million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}